Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kerri X, Yan"'
Autor:
James Dru, Diana V. Selverian, M.L Constanzer, Tuli Ahmed, Kevin J. Petty, Anup K. Majumdar, Howard E. Greenberg, Jacqueline B. McCrea, Kerri X. Yan, Glen S. Frick, Suna Barlas, Walter K. Kraft
Publikováno v:
The Journal of Clinical Pharmacology. 47:744-750
Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam 2 mg +/- oral aprepitant 125 mg. The hypoth
Autor:
Marina De Smet, Haiyuan Zhu, Zissi Matthijs, Katelijn Decochez, Hengchang Song, Amy O. Johnson-Levonas, Hannah O Maynor, Ronda K. Rippley, Jutta Miller, Kerri X. Yan, John A. Wagner, Bart Keymeulen, Keith Gottesdiener, Michael J. Davies, Kerry Riffel, Wesley Tanaka
Publikováno v:
Drugs in R & D. 7:99-110
Background: The objective of these studies was to evaluate the pharmacokinetics and pharmacodynamics of MK-0767, a prototypical dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, following administration of single and multiple oral
Publikováno v:
Journal of Chromatography B. 814:29-36
Turbulent flow chromatograph (TFC) is a technique for the direct and efficient analysis of drugs and metabolites in biological matrices. We report here TFC on-line with an HPLC-MS/MS assay for the determination of 5-[2,4-dioxothiazolidin-5-yl)methyl]
Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist
Autor:
Howard E. Greenberg, Natalie D. Matthews, Ronda K. Rippley, Kerri X. Yan, Gary A. Herman, John A. Wagner
Publikováno v:
Journal of clinical pharmacology. 47(3)
MK-0767, a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, has been studied as a potential treatment of type 2 diabetes and dyslipidemia. The pharmacokinetics and interconversion of (+)-(R)-MK-0767 and (-)-(S)-MK-0767 were
Autor:
Katelijn, Decochez, Ronda K, Rippley, Jutta L, Miller, Marina, De Smet, Kerri X, Yan, Zissi, Matthijs, Kerry A, Riffel, Hengchang, Song, Haiyuan, Zhu, Hannah O, Maynor, Wesley, Tanaka, Amy O, Johnson-Levonas, Michael J, Davies, Keith M, Gottesdiener, Bart, Keymeulen, John A, Wagner
Publikováno v:
Drugs in RD. 7(2)
The objective of these studies was to evaluate the pharmacokinetics and pharmacodynamics of MK-0767, a prototypical dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, following administration of single and multiple oral doses
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 813(1-2)
A sensitive and selective analytical method for the enantioselective determination of MK-0767, a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, in human plasma has been developed and validated. The chromatography is based
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 27(5)
A sensitive, specific, and robust liquid chromatography (LC)/mass spectrometry (MS)/MS method has been developed and validated for a novel M3 muscarinic receptor antagonist (I) and its active 5-OH metabolite (II) in human plasma. The assay involves a
Autor:
Ronda K. Rippley, Jutta Miller, Keith Gottesdiener, Kerri X. Yan, C. Thach, John A. Wagner, Hengchang Song, David Hreniuk, K. C. Lasseter
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P58
This analysis investigated the effect of age and gender on the pharmacokinetics (PK) of MK-0767, a dual PPARα/γ agonist, in healthy men and women. Sixteen healthy elderly men and women received single doses of 10 mg MK-0767 (n=12; 6 males, 6 female